442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy

• Jennifer Sims,
• Patrick Brune,
• René Hoet,
• Emmanuel Valentin,
• LE Suong,
• Sophie Agaugué,
• Paul Frohna

Affiliations

Jennifer Sims

Aff1 grid.21729.3f0000000419368729Columbia University New York NY USA

Patrick Brune

1Imcheck Therapeutics, Marseille, France

René Hoet

1Imcheck Therapeutics, Marseille, France

Emmanuel Valentin

1Imcheck Therapeutics, Marseille, France

LE Suong

1Imcheck Therapeutics, Marseille, France

Sophie Agaugué

1Imcheck Therapeutics, Marseille, France

Paul Frohna

1Imcheck Therapeutics, Marseille, France